Health-related quality-of-life results from the phase 3 OPTIMISMM study: pomalidomide, bortezomib, and low-dose dexamethasone versus bortezomib and low-dose dexamethasone in relapsed or refractory multiple myeloma

Katja Weisel*, Meletios Dimopoulos, Philippe Moreau, Munci Yagci, Alessandra Larocca, Abraham S. Kanate, Filiz Vural, Nicola Cascavilla, Supratik Basu, Peter Johnson, Peter Byeff, Marek Hus, Paula Rodríguez-Otero, Ercan Muelduer, Pekka Anttila, Patrick J. Hayden, Maria Theresa Krauth, Paulo Lucio, Dina Ben-Yehuda, Larisa MendeleevaShien Guo, Xin Yu, Lara Grote, Tsvetan Biyukov, Sujith Dhanasiri, Paul Richardson

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

10 Scopus citations

Fingerprint

Dive into the research topics of 'Health-related quality-of-life results from the phase 3 OPTIMISMM study: pomalidomide, bortezomib, and low-dose dexamethasone versus bortezomib and low-dose dexamethasone in relapsed or refractory multiple myeloma'. Together they form a unique fingerprint.

Medicine & Life Sciences